News: Mylan Inc (MYL.OQ)
33.99USD
4:00pm EDT
$0.43 (+1.28%)
$33.56
$33.73
$34.62
$33.54
1,261,976
1,207,039
$34.62
$22.51
Mylan earnings rise, but dollar drags on revenue
- Generic drugmaker Mylan Inc reported a quarterly profit that edged past Wall Street expectations but said weakness of the Indian and Japanese currencies against the dollar would put 2013 revenue at the low end of its forecast range of $7 billion to $7.4 billion.
UPDATE 2-Mylan earnings rise, but dollar drags on revenue
Aug 1 - Generic drugmaker Mylan Inc reported a quarterly profit that edged past Wall Street expectations but said weakness of the Indian and Japanese currencies against the dollar would put 2013 revenue at the low end of its forecast range of $7 billion to $7.4 billion.
Mylan second quarter earnings rise, but foreign exchange drags
Aug 1 - Generic drugmaker Mylan Inc said on Thursday that its second-quarter earnings rose, but forecast 2013 revenue would be at the low end of an expected $7 billion to $7.4 billion range because of the weakening of India's and Japan's currencies against the dollar.
Mylan says court dismisses some of Teva's patent claims on MS drug
- A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.
Mylan says court dismisses some of Teva's patent claims on MS drug
July 16 - A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.
DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan
NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.
Warner Chilcott buy may be Actavis' best takeover defense
NEW YORK - Generic drugmaker Actavis , the subject of intense takeover speculation, may have found its best defense: a potential purchase of Warner Chilcott Plc , a specialty pharmaceutical company that has been for sale on and off for years.
Market Chatter-Corporate finance press digest
May 15 - The following corporate finance-related stories were reported by media on Wednesday:
Actavis rejected $15 billion offer from Mylan: source
NEW YORK - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.
Actavis rejected $15 billion offer from Mylan - source
NEW YORK, May 14 - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.
Press Releases
- Mylan Launches Generic Version of Qualaquin® Capsules
- Incidence of Anaphylaxis During Winter Events Highlights Importance of Adding a Preparedness Checklist to Holiday Planning
- Mylan Announces Pricing of Senior Notes
- Mylan Launches Generic Version of Atacand HCT®
- Mylan Commemorates 24th World AIDS Day
- Mylan Selected As One of the Leading Suppliers to the South African National Department of Health 2013/2014 Antiretroviral Tender
- Mylan Launches Generic Detrol® Tablets
- Moody's and Standard & Poor's Upgrade Mylan to Investment Grade Credit Ratings
- Mylan Launches Generic Version of Revatio® Tablets
- Mylan Announces Ortho Tri-Cyclen Lo® Settlement Agreement

